Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices

Lubrano, Ennio; Scriffignano, Silvia; Azuaga, Ana Belén; Ramírez, Julio; Cañete, Juan D.; Perrotta, Fabio Massimo

doi:10.1136/rmdopen-2020-001170

Cited by 27 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a prospective international study of 410 patients with PsA that evaluated patient- and physician-perceived remission and LDA (measured by ‘yes/no’ questions), physicians appeared to consider patients to be in remission more often than patients did, whereas the opposite was true for LDA [ 15 ]. Similarly, a recent post hoc analysis of 223 patients with PsA showed disagreement between HCP-judged remission (measured by a ‘yes/no’ question), and patients considering themselves to be ‘well’ (measured by Patient Acceptable Symptom State, a single-question tool with potential for use as an alternative measure of disease activity in patients with PsA in clinical practice [ 16 ]) [ 17 ]. Additionally, a multicenter European study of 460 patients with PsA revealed discordance between HCP and patient global assessments of disease activity [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey

Lim¹,

Richette

Queiró³

et al. 2021

Rheumatol Ther

View full text Add to dashboard Cite

Introduction The objective of this report was to evaluate perceptions of psoriatic arthritis (PsA) treatment and satisfaction with healthcare professional (HCP) communication among patients with PsA in Australia, compared with overall global perceptions. Methods Data were collected via a global and country-specific survey (The Harris Poll; November 2, 2017–March 12, 2018). Eligible patients were ≥ 18 years old, had been diagnosed with PsA > 1 year prior, had seen a rheumatologist or dermatologist within the past 12 months, and had previously received ≥ 1 conventional synthetic or biologic disease-modifying antirheumatic drug. Data reported by patients included baseline demographics, overall health, time since PsA diagnosis, PsA severity, satisfaction with current PsA medication and management, and experiences regarding communication with their HCP. Descriptive statistics were obtained. Results Most patients in Australia were very or somewhat satisfied with their PsA medication, and reported always or often taking their medication exactly as directed by their HCP. However, the majority still experienced symptoms, reported their overall health as poor or fair, and would change something about their PsA medication. While the majority of patients in Australia were satisfied with the communication with their HCP, most would prefer increased communication but some felt that asking too many questions would affect the quality of their care. Perceptions in Australia were similar to global perceptions. Conclusions Although most patients with PsA in Australia were satisfied with their disease management and communication with their HCP, many still experienced symptoms, would change something about their PsA medication, and would prefer increased communication with their HCP. Supplementary Information The online version contains supplementary material available at 10.1007/s40744-021-00297-w.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey

Lim¹,

Richette

Queiró³

et al. 2021

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

“…DAPSA was calculated by adding the number of tender and swollen joints, pain on VAS, PtGA, and CRP (mg/dl) [ 17 ]. The PASS is a single question tool to evaluate the level of symptoms at which patients consider themselves well [ 9 ]. The PsAID was also assessed [ 10 ].…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, the aim of this clinical study was to look at the MDA divided into the seven cutoffs (from 1/7 to 7/7) and analyzing which domains were more frequently achieved, in particular in those not satisfying the MDA, namely from 1/7 to 4/7, in a group of PsA patients, as a “climb” towards MDA. A secondary aim was to assess the relationship between MDA, categorized into seven cutoffs, with the Patient Acceptable Symptoms State (PASS) [ 9 ], the Psoriatic Arthritis Impact of the Disease (PsAID) [ 10 ], the Disease Activity for Psoriatic Arthritis (DAPSA) [ 11 ], and the Physician Global Assessment (PhGA).…”

Section: Introductionmentioning

confidence: 99%

The “Climb” Towards Minimal Disease Activity in Psoriatic Arthritis

2021

Self Cite

View full text Add to dashboard Cite

Introduction: Minimal disease activity (MDA) is a validated outcome measure in psoriatic arthritis (PsA) defining a low disease activity state with a cutoff of 5/7. The main aim of the study was to look at the MDA divided into in the seven cutoffs, analyzing the more frequently achieved domains. The relationship between MDA, PASS, PsAID, DAPSA, and the PhGA in all cutoffs was also evaluated. Methods: Cross-sectional analysis on PsA patients satisfying CASPAR criteria. An assessment of disease activity, treatment target, function, and impact of disease was performed. Patients achieving MDA were compared to patients not achieving MDA in order to evaluate the most frequent domain found.Results: Ninety-three PsA patients were enrolled. MDA was satisfied in 44/93, while in 47 MDA ranged from 1/7 to 4/7. Among the seven domains, Leeds Enthesitis Index (LEI) was the most frequent domain found in all patients. In those not in MDA, BSA B 3 (70%) and swollen joints count B 1 (68%) were also well represented. The domains with a lower percentage of patients not in MDA were HAQ-DI B 0.5 (38.8%), tender joint count B 1 (23%), PtGA B 20 (4.2%) and VAS pain B 15 mm (2%). There was a growing trend, from MDA 1/7 to MDA 7/7 in the percentage of patients in PASS yes, in PsAID B 4, and in DAPSA B 14. Conclusions: The present study detailed the domains more achieved also in those patients not in MDA showing that ''physician-driven'' domains are more frequently achieved in our patients.

show abstract

“…The clinical assessment encompassed the number of tender and swollen joints (out of the 68/66 assessed joints), enthesitis, and dactylitis. Enthesitis was assessed by using the Leeds Enthesitis Index (LEI) [ 20 ], and dactylitis as present/absent, as published elsewhere [ 21 , 22 ]. Skin assessment was performed using the body surface area (BSA).…”

Section: Methodsmentioning

confidence: 99%

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction The aim of this study was to evaluate the impact of comorbidities on disease activity, patient’s impact of the disease, patient global assessment, and function in psoriatic arthritis (PsA). Methods Consecutive PsA patients were enrolled in this cross-sectional study. During the visit, the patients underwent a complete physical examination and clinical/laboratory data were collected, including type and number of comorbidities, recorded as simple comorbidity count (SCC). Disease activity was assessed using the Disease Activity Score for Psoriatic Arthritis (DAPSA) and the Minimal Disease Activity (MDA) was also evaluated. The Psoriatic Arthritis Impact of Disease (PsAID), the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the Patient Global Assessment of disease activity (PtGA) were also collected. Results A total of 144 patients were enrolled. At least one comorbidity was registered in 104 (72.2%) patients. The SCC was associated with DAPSA ( β = 1.48, p = 0.013), PsAID ( β = 0.41, p < 0.01), HAQ-DI ( β = 0.11, p < 0.01) and PtGA ( β = 0.50, p < 0.01). The comorbidities that showed an impact on outcome measures were anxiety and fibromyalgia (FM). Anxiety showed an impact on DAPSA ( β = 14.46, p < 0.001), PsAID ( β = 1.98, p = 0.039) and HAQ-DI ( β = 0.54, p = 0.036). FM showed an impact on DAPSA ( β = 6.46, p = 0.025), PsAID ( β = 2.88, p < 0.001), HAQ-DI ( β = 0.70, p < 0.001), PtGA ( β = 2.00, p = 0.014), and MDA ( β = − 2.79, p = 0.01). The median PtGA value was different among patients with different numbers of comorbidities . Conclusions This study showed that comorbidities, either as a simple comorbidity count number or as single comorbidity, might have an impact on the main domains affecting PsA patients in real clinical practice.

show abstract

Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices

Cited by 27 publications

References 28 publications

Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey

Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey

The “Climb” Towards Minimal Disease Activity in Psoriatic Arthritis

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study

Contact Info

Product

Resources

About